BAC vs BBIO Stock Comparison

BBIO currently leads BAC in this stock comparison, with AIQ scores of 64 vs 58. The clearest difference is momentum, while BAC has the stronger risk resilience profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 6 points
BAC
Financial Services
vs
BBIO
Healthcare
BAC
Bank of America Corporation
Price
$51.02
Day move
+1.01%
AIQ Score
58/100
Best edge
Risk Resilience
Sector
Financial Services
BBIO
BridgeBio Pharma, Inc.
Leads
Price
$78.30
Day move
+0.17%
AIQ Score
64/100
Best edge
Momentum
Sector
Healthcare

What is the main difference between BAC and BBIO?

BBIO leads the current stock comparison as BridgeBio Pharma, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Bank of America Corporation vs BridgeBio Pharma, Inc.

Data as of Nov 15, 2026· market close· Cross-sector · Financial Services vs Healthcare· Coverage 65/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 4/10

BBIO leads

BBIO leads by 6 AIQ points, primarily on Momentum, having only recently taken the lead back from BAC.

Fragile: 4 of 6 evidence groups support BBIO, the lead recently changed hands, and its current signal state is conflicted.

Evidence agreement: 4 of 6Comparison trend: Reversed
BAC

Bank of America Corporation

AIQ Score
58/100
AIQ Edge Score
6/10
BBIO

BridgeBio Pharma, Inc.

Leads
AIQ Score
64/100
AIQ Edge Score
7/10

The Algovestiq AIQ Score currently favors BBIO over BAC, 64 versus 58 as of Nov 15, 2026. BBIO's advantage is driven primarily by stronger momentum, while BAC holds the stronger risk resilience profile. BBIO also shows the stronger technical structure relative to its 50-day moving average. 4 of 6 covered evidence groups favor BBIO today, and the comparison is rated Fragile on stability: the lead has already changed hands inside the comparison window. BBIO lead: Reversed — BAC led by 12 AIQ points 30 sessions ago; BBIO now leads by 6.

Compare Bank of America Corporation and BridgeBio Pharma, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Total return with distributions reinvested, from daily closes.

BAC
+24.0%
BBIO
+69.8%

Total return comparison

Growth of $10,000, distributions reinvested

BAC $12,399 · BBIO $16,985

Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.

Compare BAC and BBIO against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

BAC advantage
0
BBIO advantage
  • Momentum37 vs 69
    BBIO +32
  • Risk Resilience83 vs 62
    BAC +21
  • Value68 vs 55
    BAC +13
  • Quality64 vs 66
    Even

4 of 6 evidence groups favor BBIO. BBIO’s edge is concentrated in momentum; BAC keeps a meaningful risk resilience edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

BAC0 AIQ

No factor moved materially.

New signals

  • OBV Bullish Divergence — bullish, volume, medium horizon (-0.4%)
BBIO+1 AIQ

Largest factor move: Quality +1

No signal started or stopped since the prior session; its 5 active signals are unchanged.

BBIO's lead widened by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — BAC and BBIO both carry a full feed there.

The central trade-off

BBIO (BridgeBio Pharma, Inc.): the stronger current systematic profile, led by momentum.

BAC (Bank of America Corporation): the counter-case, on risk resilience, value, valuation.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

BBIO

BBIO on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

BBIO

BBIO on combined revenue and EPS growth.

Value

BAC

BAC on the peer-relative Value factor, by 13 points.

Momentum

BBIO

BBIO on the Momentum factor, by 32 points.

Lower downside

BAC

BAC on Risk Resilience, by 21 points.

Analyst upside

BBIO

BBIO on implied upside to the consensus price target.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureBACBBIONote
Implied upside to target+24.1%+42%BBIO has more room
Target dispersion+25.3%+62.1%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering2522Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

4 of 6 covered evidence groups favor BBIO. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreBBIO58 vs 64
FundamentalsBBIOon balancerevenue growth -3.3% vs 44.9%; EPS growth -23.8% vs 46.2%; TTM ROE 2.3% vs 3.4%; gross margin 60.4% vs 93.5%; operating margin 22.4% vs -43.4% — BBIO takes 4 of 5 decided legs, not all of them
ValuationBACValue 68 vs 55
TechnicalsBBIOPrice vs 50-day -5.6% vs 11.9%; vs 200-day -7% vs 7.7%
Risk ResilienceBACRisk Resilience 83 vs 62
Analyst expectationsBBIOTarget upside 24.1% vs 42%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BAC and BBIO and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is moderate at 6 points.
  • The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
  • The lead has swung materially session to session. (argues the conclusion is provisional)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)
  • Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on BBIO.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

BBIO lead: Reversed — BAC led by 12 AIQ points 30 sessions ago; BBIO now leads by 6.

May 27BAC leads above the line · BBIO leads belowNov 13
Today
BBIO +6
58 vs 64
7 sessions ago
BBIO +4
58 vs 62
30 sessions ago
BAC +12
62 vs 50
90 sessions ago
BAC +12
71 vs 59

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

BACConflicted

2 bullish / 2 bearish / 1 neutral, conflicted

Only BAC

  • Bollinger Band Squeeze — neutral, volatility, short horizon (4.5%)
  • Downtrend Structure Active — bearish, trend, long horizon
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon
  • OBV Bullish Divergence — bullish, volume, medium horizon (-0.4%)
BBIOConflicted

2 bullish / 2 bearish / 1 neutral, conflicted

Only BBIO

  • ADX Trend Strengthening — neutral, trend, medium horizon
  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.38x)
  • TRIX Bullish Signal — bullish, momentum, short horizon

Both carry 1 more signal that do not separate them: Death Cross Active.

BBIO leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

BACNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.01%, AIQ 0 points).

BBIOConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +0.17%, AIQ +1 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1BAC closes the Momentum gap — currently 32 points behind, the largest single contributor to BBIO's edge.
  2. 2BAC's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3BBIO's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

BBIO leads on balance
MetricBACBBIO
Revenue growth (YoY)-3.3%44.9%
EPS growth (YoY)-23.8%46.2%
Gross margin60.4%93.5%
Operating margin22.4%-43.4%
Return on equity (TTM)2.3%3.4%
Debt to equity1.28-1.5

Performance

BBIO leads 6 of 6 windows
MetricBACBBIO
1 week (5 sessions)3.2%5.4%
1 month (20 sessions)-0.4%17.9%
3 months (63 sessions)-20.1%-2%
6 months (126 sessions)2.5%18.4%
Year to date-7.2%2.4%
1 year (252 sessions)-5.7%18.2%

Technicals

BBIO has the stronger structure
MetricBACBBIO
RSI (14)45.965
ADX (14)27.238.9
Price vs 50-day-5.6%11.9%
Price vs 200-day-7%7.7%
Volatility (1M, annualized)24.8%39.1%

Risk

BAC is the more resilient
MetricBACBBIO
Beta0.790.95
Sharpe ratio-0.220.55
Sortino ratio-0.290.84
Max drawdown-23.7%-29.8%
Current drawdown-21.3%-13.2%
Annualized volatility22.4%44.1%
Value at risk (95%)-2.6%-4%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, BAC or BBIO?

On the Algovestiq AIQ Score, BBIO is the stronger of the two as of Nov 15, 2026, scoring 64 against BAC's 58. The edge comes from momentum. BAC is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is BAC or BBIO the better buy right now?

BBIO carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 4 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the lead has already changed hands inside the comparison window. Treat the lead as provisional.

Why does the AIQ Score favor BBIO over BAC?

The composite weights Quality, Value, Momentum and Risk Resilience. BBIO leads Momentum by 32 points; BAC leads Risk Resilience by 21 points; BAC leads Value by 13 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, BAC or BBIO?

Analyst price targets imply +24.1% upside for BAC and +42% for BBIO, so the Street currently favors BBIO. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, BAC or BBIO?

BAC is the better-valued of the two on the peer-relative Value factor. BAC on the peer-relative Value factor, by 13 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, BAC or BBIO?

BBIO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, BAC or BBIO?

BBIO on the Momentum factor, by 32 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, BAC or BBIO?

BAC is the more resilient of the two, so the other name carries the higher downside risk. BAC on Risk Resilience, by 21 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is BAC more profitable than BBIO?

The profitability evidence is mixed: gross margin 60.4% vs 93.5%; operating margin 22.4% vs -43.4%; ttm roe 2.3% vs 3.4%. BAC leads on one measure and BBIO on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is BBIO's lead over BAC getting stronger or weaker?

BBIO lead: Reversed — BAC led by 12 AIQ points 30 sessions ago; BBIO now leads by 6. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.

What would change the BAC vs BBIO verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: BAC closes the Momentum gap — currently 32 points behind, the largest single contributor to BBIO's edge; BAC's Death Cross Active resolves — a bearish trend rule currently active against it; BBIO's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about BAC and BBIO?

BAC: 2 bullish / 2 bearish / 1 neutral, conflicted. BBIO: 2 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on BAC is Death Cross Active (bearish, long horizon). On BBIO it is Death Cross Active (bearish, long horizon).

Compare BAC and BBIO with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.